Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

0(0%)

Results Posted

100%(2 trials)

Terminated

1(25%)

Phase Distribution

Ph not_applicable

25%

Ph phase_2

25%

Ph phase_3

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

1(25.0%)

Phase 3Large-scale testing

2(50.0%)

N/ANon-phased studies

1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Other(1)

Detailed Status

Completed2

Terminated1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 3

Trials by Phase

Phase 21 (25.0%)

Phase 32 (50.0%)

N/A1 (25.0%)

Trials by Status

completed250%

terminated125%

unknown125%

Recent Activity

0 active trials

Showing 4 of 4

unknownphase_3

Amantadine for COVID-19

NCT04894617

terminatedphase_2

Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis

NCT00755950

completedphase_3

Rhodiola Rosea Therapy of Major Depressive Disorder

NCT01098318

completednot_applicable

Intracranial Pressure in Experimental Models of Headache

NCT01288781

Clinical Trials (4)

Showing 4 of 4 trials

NCT04894617Phase 3

Amantadine for COVID-19

Unknown

NCT00755950Phase 2

Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis

Terminated

NCT01098318Phase 3

Rhodiola Rosea Therapy of Major Depressive Disorder

Completed

NCT01288781Not Applicable

Intracranial Pressure in Experimental Models of Headache

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4